Business
BrainsWay Announces First Coverage Policy for Accelerated Deep TMS™
New Premera Blue Cross Blue Shield® policy extends to both adolescent and adult depression patientsBURLINGTON, Mass. and JERUSALEM, Jan. 07, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today announced that Premera Blue Cross Blue Shield®, a company with over 2.8 million covered lives serving Alaska and Washington state, has adopted a new final medical policy which, among othe
About this update from Brainsway Ltd
[{"type":"image","alt":"BrainsWay","displaySize":"","headline":null,"caption":"BrainsWay","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":219,"url":"https://media.zenfs.com/en/globenewswire.com/c68c48f9a0ccb3343f1124cb0b8b7c2f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/6QrLgY5gLW7VtP5hZFuKtg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTMwNztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/c68c48f9a0ccb3343f1124cb0b8b7c2f","width":300,"height":219}},"lazy":false},{"type":"text","content":"New Premera Blue Cross Blue Shield® policy extends to both adolescent and adult depression patients","length":99,"tagName":"p"},{"type":"text","content":"BURLINGTON, Mass. and JERUSALEM, Jan. 07, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today announced that Premera Blue Cross Blue Shield®, a company with over 2.8 million covered lives serving Alaska and Washington state, has adopted a new final medical policy which, among other developments, expands coverage to include patients ages 15 and older with moderate to severe major depressive disorder (MDD) treated with BrainsWay’s accelerated SWIFT™ (Short-course with Intrinsic Field Targeting) Deep TMS™ protocol.","length":641,"tagName":"p"},{"type":"text","content":"“We are elated at Premera’s decision to formally adopt a policy covering our SWIFT depression protocol, which marks a first among payers. SWIFT entails significantly fewer days spent in the clinic, allowing patients to achieve meaningful improvement more quickly than our standard Deep TMS protocol,” stated Hadar Levy, Chief Executive Officer of BrainsWay.","length":357,"tagName":"p"},{"type":"text","content":"BrainsWay’s SWIFT depression protocol consists of an acute phase of five treatment sessions (ten minutes each) per day for six days, followed by two sessions per day once a week for four weeks, for a total of 38 sessions. There is no need for any functional MRI or other expensive neuronavigational equipment.","length":309,"tagName":"p"},{"type":"text","content":"“BrainsWay’s clinical trial and real-world evidence demonstrates comparable response and remission outcomes for its SWIFT accelerated depression protocol when compared to the standard Deep TMS protocol. We are committed to continui...